MoonLake Immunotherapeutics (NasdaqCM: MLTX)
Health Care · Biotechnology · CH
$15.56
-5.53% today · -69.3% 1Y
MoonLake Immunotherapeutics (NasdaqCM: MLTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.40B and employs 130 people.
Over the last twelve months the share price has lost 69.3%, trading between 5.95 and 62.75.
Tweenvest scores MoonLake Immunotherapeutics across four factors: quality 27/100. Its strongest factor is quality.
MLTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.40B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.81
- Dividend yield
- —
- Beta (5Y)
- 1.07
- 52-week high
- $62.75
- 52-week low
- $5.95
- Avg volume (3M)
- —
- Shares outstanding
- 85.11M
- Employees
- 130
- Next earnings
- —
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
- ISIN
- KY61559X1045
- Founded
- 2021
- Listed since
- Oct 20, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €894.20 | +1.71% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.